Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dolasetron
Drug ID BADD_D00702
Description Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Indications and Usage For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
Marketing Status Discontinued
ATC Code A04AA04
DrugBank ID DB00757
KEGG ID D07867
MeSH ID C060344
PubChem ID 60654
TTD Drug ID D00YLW
NDC Product Code Not Available
Synonyms dolasetron | 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)- | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate | indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | dolasetron mesylate | dolasetron mesylate monohydrate | 1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate | dolasetron mesilate monohydrate | 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1) | Anzemet | MDL 73,147EF | MDL-73147EF | MDL 73147EF
Chemical Information
Molecular Formula C19H20N2O3
CAS Registry Number 115956-12-2
SMILES C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Influenza like illness08.01.03.010--
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Intestinal obstruction07.13.01.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nodal arrhythmia02.03.02.005--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oliguria20.01.03.004--Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005--
Peripheral ischaemia24.04.03.002--
Phlebitis24.05.03.001; 12.02.01.002--
Photophobia06.01.01.004; 17.17.02.006--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyuria20.02.03.002--Not Available
Prothrombin level increased13.01.02.011--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages